Post hoc analysis of 5772 patients with knee or hip osteoarthritis in phase 2/3 trials: fasinumab gave dose-related rises in bone formation markers and CRP, larger in those who developed arthropathies; CRP rises reversed after the last dose.
Secondary analysisn = 5,772
Banerjee et al. Signals for mineralization and inflammation are observed following treatment with fasinumab, a specific nerve growth factor inhibitor